



PRESS RELEASE

Mabqi and Syndivia announce the execution of an exclusive licensing agreement for their jointly discovered antibody-drug conjugate (ADC)

Montpellier, Strasbourg, January 8th, 2026 – Mabqi S.A.S. (“Mabqi”) today announced that Syndivia S.A.S. (“Syndivia”) had exercised an option with Mabqi on a jointly discovered antibody-drug conjugate (ADC) acquired by a Pharma company.

This option was exercised as part of a research collaboration launched in 2023 between Mabqi and Syndivia to discover and develop a new ADC drug candidate with indications in Prostate Cancer.

This step marked a major milestone in the collaboration between the two companies, combining their complementary strengths: Mabqi’s LiteMab Antibody Discovery Studio and Syndivia’s GeminiMab ADC platform. The antibody was discovered through the LiteMab discovery studio, tailored to meet the precise functional requirements of the final drug candidate, including affinity, developability, and pharmacological properties. Syndivia subsequently designed the final ADC candidate and carried out the full preclinical characterization.

“We are delighted that Syndivia has exercised this option and successfully demonstrated the potency of this candidate within such a short timeframe”, said Sylvain Yon, CEO of Mabqi. “The combination of our LiteMab Antibody Discovery Studio with Syndivia’s cutting-edge conjugation platform has proven to be a highly effective approach, enabling the rapid discovery of a drug candidate with strong clinical potential. Through this collaboration, Mabqi reinforces its focus on advancing research in areas of significant medical need by joining forces with partners who contribute complementary expertise and technologies, creating synergies that accelerate the discovery of new treatments for patients.”

“We are pleased to collaborate with Mabqi,” said Sasha Koniev, CEO of Syndivia. “Their proven expertise in antibody discovery and selection perfectly complements our strengths in ADC development. This partnership underscores our shared vision of bringing transformative therapies to patients in need.”



About Mabqi SAS

Founded in 2017, Mabqi is a biotechnology company specializing in the discovery and development of next-generation human antibodies. Its proprietary LiteMab Antibody Discovery Studio integrates a comprehensive suite of human synthetic naïve antibody libraries with an AI-enhanced display technology, enabling unmatched diversity and precision in therapeutic lead identification.

Alongside its platform capabilities, the company is advancing a pipeline of innovative oncology assets and is building strong expertise in conditionally active pH-sensitive antibodies and antibody-drug conjugates (ADCs).

<https://mabqi.com>

About Syndivia SAS

Syndivia is a biotechnology company focused on the design and development of innovative antibody-drug conjugates. Its proprietary technology enables the creation of next-generation ADCs with optimized therapeutic profiles, aiming to expand treatment options for patients with cancer.

<https://syndivia.com>

CONTACTS

Mabqi

Sylvain Yon, CEO

business@mabqi.com

Syndivia

Sasha Koniev, CEO

enquiry@syndivia.com